Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,856 total articles

Smithfield Foods Awards 12 Impact Grants Nationwide

Smithfield Foods Awards 12 Impact Grants Nationwide

Smithfield Foods has awarded over $280,000 in Impact Grants to 12 nonprofit organizations addressing community needs such as hunger relief, education, and local infrastructure. This funding builds on their prior $24 million investment in 2025 and supports initiatives including food security, literacy, emergency services, and youth programs in areas…

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio, a clinical-stage biotech company focusing on therapies for Alzheimer's and Parkinson's diseases, announced the pricing of an underwritten public offering of common stock and warrants aiming to raise approximately $15 million. The proceeds will primarily support continued clinical development of buntanetap and general corporate purposes…

Freshworks Announces Winners of the 2026 Global Customer Awards

Freshworks Announces Winners of the 2026 Global Customer Awards

Freshworks Inc. announced the winners of its inaugural 2026 Global Customer Awards, recognizing customers from various industries who have successfully leveraged Freshworks' AI-enabled service platforms to drive significant operational efficiencies, improve customer satisfaction, and advance digital transformation. The awards highlight achievements…

Daniel Kelly Joins Talen as General Counsel and Corporate Secretary

Daniel Kelly Joins Talen as General Counsel and Corporate Secretary

Talen Energy Corporation announced the appointment of Daniel Kelly as General Counsel and Corporate Secretary. Kelly brings 25 years of legal and governance experience, previously holding a senior role at Vistra Corp. He replaces John Wander, who has retired after three years in the position. Kelly will oversee legal, regulatory, and corporate gove…

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Madrigal Pharmaceuticals announced that new data from its MASH program will be presented at the EASL Congress 2026. The data includes secondary analyses from Phase 3 trials demonstrating Rezdiffra's positive impact on lipid profiles and portal hypertension risk markers in patients with metabolic dysfunction-associated steatohepatitis (MASH). The pr…

EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2026 and Announces the order for two Modern 82,000 DWT Kamsarmax Bulk Carriers

EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2026 and Announces the order for two Modern 82,000 DWT Kamsarmax Bulk Carriers

EuroDry Ltd., a US-listed drybulk shipping company, reported a positive turnaround in Q1 2026 with net income attributable to controlling shareholders of $0.26 million, a significant improvement from a loss in the same period last year. The company saw a 38.9% increase in net revenues driven by a doubling of the average time charter equivalent rate…

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

Dyne Therapeutics has commenced the Phase 3 FORZETTO clinical trial testing z-rostudirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The 72-week, placebo-controlled trial aims to confirm the drug's efficacy and safety with a primary endpoint focused on muscle function. The trial protocol aligns with FDA guidelines to…

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, a patented next-generation non-racemic MDMA therapeutic developed by PharmAla Biotech. The acquisition positions Jupiter at the forefront of MDMA-based psychedelic medicine, coinciding with President Trump's Executive Order accelera…

Rail Vision: Quantum Transportation Successfully Integrates Google’s Public Surface-Code Dataset into its Quantum Error Correction Transformer

Rail Vision: Quantum Transportation Successfully Integrates Google’s Public Surface-Code Dataset into its Quantum Error Correction Transformer

Rail Vision Ltd., through its majority-owned subsidiary Quantum Transportation Ltd., has successfully integrated Google's public surface-code dataset into its quantum error correction transformer pipeline. This advancement enhances the ability to train and benchmark quantum error correction algorithms on credible external data, reducing technical r…

Bread Financial launches 2025 Sustainability Report

Bread Financial launches 2025 Sustainability Report

Bread Financial (NYSE: BFH) released its 2025 Sustainability Report emphasizing advances in embedding sustainability across operations, technology modernization, and governance. The report highlights improved financial resilience and credit ratings, customer experience enhancements, strong associate engagement, increased community impact, and envir…

Mobilicom Secures New Design Wins with Two U.S. Tier-1 Drone Manufacturers for Cybersecure Datalink Integration in ISR Platforms

Mobilicom Secures New Design Wins with Two U.S. Tier-1 Drone Manufacturers for Cybersecure Datalink Integration in ISR Platforms

Mobilicom Limited announced it has secured new design wins with two leading U.S. Tier-1 defense drone manufacturers for small-sized ISR drone platforms. The agreements highlight growing adoption of Mobilicom's cybersecure SkyHopper datalink solutions and ICE electronic warfare resistance suite, furthering the company's strategic objectives for 2026…

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) has announced that its senior management team will participate in several upcoming investor conferences, including Goldman Sachs' and Jefferies' healthcare events. The company provides life-saving solutions against public health threats like smallpox, mpox, botulism, Ebola, anthrax, and opioid overdoses, aimin…

Quantum Cyber Files Provisional Patent for Quantum-Navigated Amphibious Autonomous Ground Vehicle Platform

Quantum Cyber Files Provisional Patent for Quantum-Navigated Amphibious Autonomous Ground Vehicle Platform

Quantum Cyber N.V. has filed a provisional patent for its SCOUT-AX6 GUARDIAN, a 6x6 amphibious autonomous ground vehicle that uses a novel quantum sensing navigation system to operate accurately in GPS-denied environments. The platform is designed for multi-domain defense missions, featuring post-quantum encrypted communications and advanced AI-dri…

KANZHUN LIMITED Announces First Quarter 2026 Financial Results

KANZHUN LIMITED Announces First Quarter 2026 Financial Results

KANZHUN LIMITED announced robust financial results for Q1 2026, with revenues increasing 7.6% year-over-year to RMB2.07 billion (US$299.9 million). Net income more than doubled to RMB1.13 billion (US$163.2 million). The company saw healthy growth in paid enterprise customers (up 10.9% to 7.1 million) and monthly active users (up 5.7% to 60.9 millio…

Syndax Announces Participation in Upcoming Investor Conferences

Syndax Announces Participation in Upcoming Investor Conferences

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company focused on cancer therapies, announced that CEO Michael A. Metzger and management will participate in several upcoming investor conferences including the TD Cowen Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. Th…